血友病分型及临床治疗
Classification and Clinical Treatment of Hemophilia
DOI: 10.12677/NS.2023.123048, PDF,   
作者: 高 曦:北京协和医学院护理学院,北京
关键词: 血友病临床分型治疗 Hemophilia Clinical Classification Treatment
摘要: 血友病是一组遗传性的凝血功能障碍的出血性疾病,由凝血因子VIII或IX基因异常所引起的先天性疾病。随着医学科技的发展,我国在研究血友病方面虽大有进步,但是我国血友病发病率仍呈逐年上升趋势。国内外学者对我国血友病临床表现以及对如何使血友病患者得到更方便的治疗等发面进行大量研究并取得一些成果。本人从血友病定义、临床分型及临床治疗等方面进行综述。
Abstract: He-mophilia is a group of hereditary coagulation disorders of bleeding disorders, caused by coagulation factor VIII or IX gene abnormalities caused by congenital diseases. With the development of medical science and technology, although great progress has been made in the study of hemophilia in China, the incidence of hemophilia in China is still increasing year by year. Domestic and foreign scholars have carried out a lot of research on the clinical manifestations of hemophilia in China and how to make hemophilia patients get more convenient treatment and have made some achievements. This article reviews the definition, clinical classification and clinical treatment of hemophilia.
文章引用:高曦. 血友病分型及临床治疗[J]. 护理学, 2023, 12(3): 342-348. https://doi.org/10.12677/NS.2023.123048

参考文献

[1] 薛峰, 杨仁池. 国家血友病登记系统建设[J]. 罕见病研究, 2022, 1(4): 370-374.
[2] Jamil, M.A., Sharma, A., Nuesgen, N., et al. (2019) F8 Inversions at Xq28 Causing Hemophilia A Are Associated with Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis. Frontiers in Genetics, 10, Article 508. [Google Scholar] [CrossRef] [PubMed]
[3] 朱履锴, 杨林花, 王刚. 血友病A患者凝血因子Ⅷ抑制物产生机制及相关遗传因素研究进展[J]. 中国医药, 2023, 18(1): 148-152.
[4] 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 血友病诊断与治疗中国专家共识(2017年版) [J]. 中华血液学杂志, 2017, 38(5): 364-370.
[5] 陈如意, 吴燕, 刘依润, 侯明霞, 宋清爽, 钟璇林, 王雪云, 谢文杰, 郭采平, 张战, 张运佳. 评价人凝血因子Ⅷ治疗甲型血友病患者的有效性和安全性[J]. 中国输血杂志, 2022, 35(12): 1220-1225.
[6] 李含, 孙竞, 周璇, 刘阳, 宋晓玲, 马庆辉. 中国重型血友病A的临床表现异质性及早期预测指标[J]. 南方医科大学学报, 2013, 33(3): 424-427.
[7] 刘凌, 冯莹, 谢玮, 庞缨, 叶絮, 周旭红. 44例获得性血友病A的病因、临床表现及诊疗的探讨[J]. 血栓与止血学, 2018, 24(1): 1-4.
[8] 曹东华, 梁英杰, 邹朋书, 陈丽莎, 马明, 薛丹. 辽宁地区24个血友病B家系的FIX基因突变分析[J]. 中国优生与遗传杂志, 2016, 24(2): 9-11+8+2.
[9] Srivastava, A., Santagostino, E., Dougall, A., et al. (2020) WFH Guidelines for the Management of Hemophilia, 3rd Edition. Haemophilia, 26, 1-158. [Google Scholar] [CrossRef] [PubMed]
[10] 张佳欣. 首款血友病基因治疗药物上市[J]. 新农村, 2023(1): 56.
[11] 严红, 任兆瑞, 曾溢滔. 血友病B基因治疗研究进展[J]. 中国医药生物技术, 2017, 12(4): 330-336.
[12] 冯大瑛. 小儿血友病C 3例报告[J]. 川北医学院学报, 1997(1): 92.
[13] 高洪臣, 丘木水, 于晓洁. 血管性血友病的研究进展[J]. 检验医学与临床, 2023, 20(6): 839-844.
[14] Andres, E., Dali-Youcef, N., Serraj, K. and Zimmer, J. (2009) Recognition and Management of Drug-Induced Cytopenias: The Example of Idiosyncratic Drug-Induced Thrombocyto-penia. Expert Opinion on Drug Safety, 8, 183-190. [Google Scholar] [CrossRef] [PubMed]
[15] 许俊堂. 肝素诱导的血小板减少症中国专家共识解读[J]. 中国循环杂志, 2018, 33(Z1): 117-120.